{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:43Z","timestamp":1790361703781,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T00:00:00Z","timestamp":1553904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12149-019-01354-9","type":"journal-article","created":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T18:02:29Z","timestamp":1553968949000},"page":"449-458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in mantle cell lymphoma"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Bosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bianchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giubbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,30]]},"reference":[{"key":"1354_CR1","volume-title":"World health organization classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. World health organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008."},{"key":"1354_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132:1647\u201356.","journal-title":"Blood"},{"key":"1354_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"key":"1354_CR4","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1182\/blood-2008-05-155507","volume":"112","author":"JJ Shah","year":"2008","unstructured":"Shah JJ, Fayad L, Romaguera J. Mantle cell international prognostic index (MIPI) not prognostic after R-hyper-CVAD. Blood. 2008;112:2583 author reply 2583-2584.","journal-title":"Blood"},{"key":"1354_CR5","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1002\/cncr.26731","volume":"118","author":"Svodoba J MatoAr","year":"2012","unstructured":"MatoAr Svodoba J, Feldman T, et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer. 2012;118:3565\u201370.","journal-title":"Cancer"},{"key":"1354_CR6","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","volume":"107","author":"T Katzenberger","year":"2006","unstructured":"Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107:3407.","journal-title":"Blood"},{"key":"1354_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M Tiemann","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29\u201338.","journal-title":"Br J Haematol"},{"key":"1354_CR8","first-page":"158","volume":"8","author":"S Gill","year":"2008","unstructured":"Gill S, Wolf M, Miles Prince H, et al. 18F Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with Mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2008;8:158\u201365.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1354_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clml.2011.03.013","volume":"11","author":"A Alavi","year":"2011","unstructured":"Alavi A, Shrikanthan S, Aydin A, et al. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2011;11:261\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1354_CR10","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1080\/10428190802216707","volume":"49","author":"L Brepoels","year":"2008","unstructured":"Brepoels L, Stroobants S, De Wever W, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma. 2008;49:1693\u2013701.","journal-title":"Leuk Lymphoma"},{"key":"1354_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/ajh.22126","volume":"86","author":"PJ Hosein","year":"2011","unstructured":"Hosein PJ, Pastorini VH, Paes FM, et al. Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol. 2011;86:841\u20135.","journal-title":"Am J Hematol"},{"key":"1354_CR12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bmt.2013.46","volume":"48","author":"JB Cohen","year":"2013","unstructured":"Cohen JB, Hall NC, Ruppert AS, et al. Association of pre-transplantation positron emission tomography\/computed tomography and outcome in mantle cell lymphoma. Bone Marrow Transplant. 2013;48:1212\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1354_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1349-7006.2010.01802.x","volume":"102","author":"U Tateishi","year":"2011","unstructured":"Tateishi U, Tatsumi M, Terauchi T, et al. Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study. Cancer Sci. 2011;102:414\u20138.","journal-title":"Cancer Sci"},{"key":"1354_CR14","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.3109\/10428194.2014.882506","volume":"55","author":"M Kedmi","year":"2014","unstructured":"Kedmi M, Avivi I, Ribakovsky E, et al. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-d-glucose-positron emission tomography\/computed tomography in mantle cell lymphoma? Leuk Lymphoma. 2014;55:2484\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1354_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clml.2013.10.007","volume":"14","author":"E Magnusson","year":"2014","unstructured":"Magnusson E, Cao Q, Linden MA, et al. Hematopoietic cell transplantation for mantle cell lymphoma: predictive value of pretransplant positron emission tomography\/computed tomography and bone marrow evaluations for outcomes. Clin Lymphoma Myeloma Leuk. 2014;14:114\u201321.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1354_CR16","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.bbmt.2017.07.006","volume":"23","author":"MG Mei","year":"2017","unstructured":"Mei MG, Cao TM, Chen L, et al. Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab. Biol Blood Marrow Transpl. 2017;23:1861\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1354_CR17","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1080\/10428194.2017.1361032","volume":"59","author":"DM Guidot","year":"2018","unstructured":"Guidot DM, Switchenko JM, Nastoupil LJ, et al. Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma. 2018;59:888\u201395.","journal-title":"Leuk Lymphoma"},{"key":"1354_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1354_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3324\/haematol.2017.184325","volume":"103","author":"R Bomben","year":"2018","unstructured":"Bomben R, Ferrero S, D\u2019Agaro T, et al. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. Hemtaologica. 2018;103:849\u201356.","journal-title":"Hemtaologica"},{"key":"1354_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1354_CR21","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"1354_CR22","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","volume":"23","author":"V Fernandez","year":"2005","unstructured":"Fernandez V, Hartmann E, Ott G, et al. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol. 2005;23:6364\u20139.","journal-title":"J Clin Oncol"},{"key":"1354_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/00001622-200109000-00005","volume":"13","author":"JP Leonard","year":"2001","unstructured":"Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr Opin Oncol. 2001;13:342\u20137.","journal-title":"Curr Opin Oncol"},{"key":"1354_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/cncr.24141","volume":"115","author":"M Garcia","year":"2009","unstructured":"Garcia M, Romaguera JE, Inamdar KV, et al. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer. 2009;115:1041\u20138.","journal-title":"Cancer"},{"key":"1354_CR25","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209\u201313.","journal-title":"J Clin Oncol"},{"key":"1354_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25\u201330.","journal-title":"J Nucl Med"},{"key":"1354_CR27","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","volume":"51","author":"M Meignan","year":"2010","unstructured":"Meignan M, Gallamini A, Haioun C, Polliack A. Report on the second international workshop on interim positron emission tomography in lymphoma held in Menton, France, 8\u20139 April 2010. Leuk Lymphoma. 2010;51:2171\u201380.","journal-title":"Leuk Lymphoma"},{"key":"1354_CR28","first-page":"1","volume":"3","author":"D Albano","year":"2018","unstructured":"Albano D, Bosio G, Re A, et al. Metabolic behaviour and prognostic value of early and end of treatment 18F-FDG PET\/CT in adult Burkitt lymphoma: role of Deauville and IHP criteria. Leuk Lymphoma. 2018;3:1\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1354_CR29","first-page":"110","volume":"36","author":"P Klener","year":"2018","unstructured":"Klener P, Fronkova E, Belada D, et al. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. HematolOncol. 2018;36:110\u20135.","journal-title":"HematolOncol"},{"key":"1354_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2967\/jnumed.116.173542","volume":"58","author":"D Lamonica","year":"2017","unstructured":"Lamonica D, Graf DA, Munteanu MC, Czuczman MS. 18F-FDG PET for measurement of response and prediction of outcome to relapsed or refractory mantle cell lymphoma therapy with bendamustine-rituximab. J Nucl Med. 2017;58:62\u20138.","journal-title":"J Nucl Med"},{"key":"1354_CR31","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00277-015-2478-9","volume":"94","author":"MS Czuczman","year":"2015","unstructured":"Czuczman MS, Goy A, Lamonica D, et al. Phase II study of bendamustine combined with rituximab in relapsed\/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol. 2015;94:2025\u201332.","journal-title":"Ann Hematol"},{"key":"1354_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","volume":"48","author":"L Kostakoglu","year":"2018","unstructured":"Kostakoglu L, Chauvie S. Metabolic tumour volume metrics in lymphoma. Semin Nucl Med. 2018;48:50\u201366.","journal-title":"Semin Nucl Med"},{"key":"1354_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12032-014-0446-1","volume":"32","author":"M Xie","year":"2015","unstructured":"Xie M, Wu K, Liu Y, et al. Predictive value of F-18 FDG PET\/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2015;32:446.","journal-title":"Med Oncol"},{"key":"1354_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12149-018-1274-8","volume":"32","author":"D Albano","year":"2018","unstructured":"Albano D, Bertoli M, Battistotti M, et al. Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma. Ann Nucl Med. 2018;32:532\u201341.","journal-title":"Ann Nucl Med"},{"key":"1354_CR35","first-page":"6","volume":"5","author":"V Proch\u00e1zka","year":"2016","unstructured":"Proch\u00e1zka V, Klugar M, Bachanova V, et al. Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy. BMJ Open. 2016;5:6.","journal-title":"BMJ Open"},{"key":"1354_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00259-018-4173-2","volume":"46","author":"D Albano","year":"2019","unstructured":"Albano D, Bosio G, Pagani C, et al. Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging. 2019;46:87\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1354_CR37","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/MNM.0b013e32832e0c13","volume":"30","author":"M Karam","year":"2009","unstructured":"Karam M, Ata A, Irish K, et al. DG positron emission tomography\/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Comm. 2009;30:770\u20138.","journal-title":"Nucl Med Comm"},{"key":"1354_CR38","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00259-010-1469-2","volume":"37","author":"C Bodet-Milin","year":"2010","unstructured":"Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluorodeoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from GOELAMS group. Eur J Nucl Med Mol Imaging. 2010;37:1633\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1354_CR39","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high\u2013tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J ClinOncol. 2016;34:3618\u201326.","journal-title":"J ClinOncol"},{"key":"1354_CR40","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","volume":"41","author":"S Kanoun","year":"2014","unstructured":"Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1354_CR41","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","volume":"130","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Schoder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130:2196\u2013203.","journal-title":"Blood"},{"key":"1354_CR42","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","volume":"41","author":"M Sasanelli","year":"2014","unstructured":"Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1354_CR43","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1354_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hon.2563","volume":"37","author":"D Albano","year":"2019","unstructured":"Albano D, Bosio G, Camoni L, et al. Prognostic role of baseline 18F-FDG PET\/CT parameters in MALT lymphoma. Hematol Oncol. 2019;37:39\u201346. \n                    https:\/\/doi.org\/10.1002\/hon.2563\n                    \n                  .","journal-title":"Hematol Oncol"},{"key":"1354_CR45","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","volume":"15","author":"M Bernard","year":"2001","unstructured":"Bernard M, Gressin R, Lefr\u00e8re F, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia. 2001;15:1785\u201391.","journal-title":"Leukemia"},{"key":"1354_CR46","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2165\/00003495-200767120-00004","volume":"67","author":"O Weigert","year":"2007","unstructured":"Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Current management of mantle cell lymphoma. Drugs. 2007;67:1689\u2013702.","journal-title":"Drugs"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01354-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-019-01354-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01354-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T00:19:41Z","timestamp":1585441181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-019-01354-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,30]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1007\/s12149-019-01354-9","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,30]]},"assertion":[{"value":"30 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all the individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}